Centre may not procure Pfizer-BioNTech Covid vaccine over high cost

At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield

As the Centre starts provisioning for one of the largest Covid-19 immunisation drives in the world, the Pfizer-BioNTech vaccine candidate seems to be an outlier, at least for now. Senior government officials have indicated that India may not procure the mRNA vaccine, which American major Pfizer and Germany’s BioNTech have developed, for the immunisation drive. The higher cost of the Pfizer vaccine, already approved by the UK and the US regulators, is among the primary reasons why other options may be preferred by India.  

At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for